Followers | 145 |
Posts | 27565 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Wednesday, December 07, 2016 1:18:00 AM
Gamida Cell
Gali Weinreb
The Israeli stem cell treatment developer also reported that it had obtained approval for a Phase III trial of NiCord for blood cancer.
Israeli stem cell developer Gamida Cell, controlled by Clal Biotechnology Industries Ltd. (TASE: CBI) and Elbit Medical Technologies Ltd. (TASE:EMTC), today published positive results in its Phase I/II trial of NiCord, the company's leading drug, for treatment of Sickle-Cell Disease (SCD). At the same time, the company also reported that it had obtained approval for a Phase III trial of NiCord for treatment of blood cancer.
All of the surviving patients in the trial were free of SCD symptoms. Gamida Cell CEO Dr. Yael Margolin said, "… the data… (indicate) that NiCord enables more patients to receive a potentially curative treatments for SCD."
Gamida Cell estimated that it would take two years to recruit patients for the Phase III NiCord trial for the treatment of blood cancer (compared with six years for a Phase III trial of another drug, since abandoned, for the treatment of blood cancer).
The Phase III trials will be conducted on 120 patients in the US and Europe. It will compare patients treated with umbilical cord blood who have undergone the company's procedure with those treated with umbilical cord blood who have not. The main goal of the trial is to demonstrate a shortening of the time needed to absorb the desirable cells in the patients' body.
The Phase I/II trial of NiCord for treatment of SCD included nine patients. The implant was absorbed in all of them. Two of the trial patients died from complications resulting from the implant, while the other seven no longer suffer from the disease. Despite the death of two patients, these results are considered better than for the existing treatment for SCD.
The Clal Biotechnology share price rose 1.58% on the news, giving the company a NIS 362 million market cap. The Elbit Medical share price was up 1%, increasing the company's market cap to NIS 170 million.
Published by Globes [online], Israel business news - www.globes-online.com - on December 6, 2016
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM